Rakuten Securities Inc. Purchases New Position in Illumina, Inc. (NASDAQ:ILMN)

Rakuten Securities Inc. acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 808 shares of the life sciences company’s stock, valued at approximately $113,000.

Other institutional investors have also added to or reduced their stakes in the company. Brown Brothers Harriman & Co. increased its position in Illumina by 460.9% in the 1st quarter. Brown Brothers Harriman & Co. now owns 129 shares of the life sciences company’s stock valued at $45,000 after acquiring an additional 106 shares during the period. State of Wyoming acquired a new position in Illumina in the 2nd quarter valued at approximately $32,000. Penserra Capital Management LLC acquired a new position in Illumina in the 1st quarter valued at approximately $64,000. Annis Gardner Whiting Capital Advisors LLC acquired a new position in Illumina in the 3rd quarter valued at approximately $30,000. Finally, VisionPoint Advisory Group LLC increased its position in Illumina by 344.6% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock valued at $34,000 after acquiring an additional 193 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Illumina news, CEO Jacob Thaysen acquired 7,330 shares of the company’s stock in a transaction on Thursday, February 22nd. The shares were purchased at an average cost of $135.29 per share, with a total value of $991,675.70. Following the completion of the purchase, the chief executive officer now owns 14,861 shares of the company’s stock, valued at $2,010,544.69. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.17% of the stock is owned by insiders.

Analysts Set New Price Targets

ILMN has been the subject of several recent research reports. Stephens restated an “overweight” rating and issued a $170.00 price target on shares of Illumina in a research report on Wednesday, April 10th. Royal Bank of Canada restated an “outperform” rating and issued a $253.00 price target on shares of Illumina in a research report on Tuesday, April 9th. OTR Global restated a “mixed” rating on shares of Illumina in a research report on Wednesday, March 20th. StockNews.com upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research report on Friday, February 16th. Finally, HSBC cut shares of Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $167.70.

Illumina Stock Up 0.5 %

Shares of NASDAQ ILMN opened at $118.29 on Thursday. The firm has a market cap of $18.84 billion, a PE ratio of -16.12 and a beta of 1.19. Illumina, Inc. has a 12-month low of $89.00 and a 12-month high of $232.23. The company’s fifty day simple moving average is $134.31 and its 200 day simple moving average is $128.15. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.26.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.13. The business had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.09 billion. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. Illumina’s revenue was up 3.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.14 earnings per share. As a group, sell-side analysts forecast that Illumina, Inc. will post 0.91 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.